Navidea Biopharmaceuticals

526 articles with Navidea Biopharmaceuticals

• Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK®

  5/11/2020

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce that the Company has regained the commercialization and distribution rights in Europe for LYMPHOSEEK® (technetium Tc99m tilmanocept) injection from Norgine B.V. (“Norgine”). Navidea and Norgine have decided, by mutual agre

• Navidea Biopharmaceuticals to Host First Quarter 2020 Earnings Conference Call and Corporate Update

  5/7/2020

  Conference Call to be Held on Thursday, May 14, 2020 at 5:00 p.m. (EDT)

• Navidea Biopharmaceuticals Provides Statement Regarding COVID-19 Pandemic

  4/22/2020

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announces the following statement regarding the impact of the COVID-19 pandemic on the company’s ongoing clinical development efforts: First, we would like to express our sincerest gratitude for all of the healthcare workers and other res

• Navidea Biopharmaceuticals Signs Letter of Intent with WorldCare Clinical to Partner on Navidea’s Rheumatoid Arthritis Clinical Imaging Workflow and Commercialization; Other Business Updates

  3/31/2020

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that it has signed a letter of intent (“LOI”) to partner with WorldCare Clinical, LLC for the Company’s rheumatoid arthritis (“RA”) diagnostic clinical imaging workflow. Per the agreement, WorldCare would serve as Navidea’s cen

• Navidea Biopharmaceuticals Announces Issuance of Patent Extension for Lymphoseek®

  3/20/2020

  Navidea Biopharmaceuticals, Inc. announced that on March 17, 2020 the U.S. Patent and Trademark Office issued a Certificate to extend the duration of U.S. patent 6,409,990 for an additional five years through May 12, 2025.

• Navidea Biopharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

  3/11/2020

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced its financial results for the fourth quarter and full year ended December 31, 2019.

• Navidea Biopharmaceuticals to Host Fourth Quarter 2019 Earnings Conference Call and Corporate Update

  3/4/2020

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced it will host a conference call and webcast on Wednesday, March 11, 2020 at 5:00 p.m. (EDT) to discuss financial results and corporate developments for the fourth quarter and full year ended December 31, 2019.

• Navidea Biopharmaceuticals Announces $4.2 Million Sale of Ohio Court Judgment and $3.4 Million Equity Raise Representing $7.6 Million in Additional Funding

  2/14/2020

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that they have executed agreements with two existing investors, including John K. Scott, Jr. (collectively, the “Investors”), to purchase approximately 4.0 million shares of the Company’s common stock, par value $0.001 per share, for aggregate gross proceeds to Navidea of approximately $3.4 million.

• Navidea Biopharmaceuticals Regains Compliance with NYSE American Continued Listing Standards

  2/14/2020

  Feb. 14, 2020 16:56 UTC DUBLIN, Ohio--( BUSINESS WIRE )-- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that following the recently-announced funding transactions, the Company is back in compliance with the NYSE American’s continued listing standards. As previously reported, on August 14, 2018, the Company received a Deficien

• Navidea Biopharmaceuticals Obtains Partial Dismissal of Claims in New York

  12/30/2019

  Navidea Biopharmaceuticals, Inc. announced that on December 26, 2019, the United States District Court, Southern District of New York ruled on several motions related to Navidea and its majority-owned subsidiary, Macrophage Therapeutics, Inc. and Dr. Michael Goldberg that substantially limited the claims that Dr. Goldberg can pursue against Navidea and MT.

• Navidea Biopharmaceuticals Announces $1.9 Million Private Placement

  12/6/2019

  Navidea Biopharmaceuticals, Inc. announced that they have executed agreements with five investors, including an existing investor, John K. Scott, Jr., to purchase approximately 2.1 million shares of the Company’s common stock, par value $0.001 per share, in a private placement for aggregate gross proceeds to Navidea of approximately $1.9 million.

• Navidea Biopharmaceuticals to Present at the 12th Annual LD Micro Main Event

  12/5/2019

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that Mr. Jed Latkin, Chief Executive Officer, will present at the 12th Annual LD Micro Main Event investor conference.

• Navidea Biopharmaceuticals Wins Summary Judgment in Ohio

  12/2/2019

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that the Court of Common Pleas for Franklin County, Ohio (the “Ohio Court”) issued a ruling in favor of Navidea in its case against Capital Royalty Partners II, L.P., et al (“CRG”).

• Navidea Biopharmaceuticals to Present at the PCG Spotlight Series Conference

  11/14/2019

  Presentation on Thursday, November 21st at 12:25pm ET

• Navidea Biopharmaceuticals Announces Preclinical Therapeutic Research Collaboration with IMV Inc. to Explore the Potential Combinatory Effect with Their Platform-Based Immunotherapies

  11/7/2019

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB), a company focused on the development of precision immunodiagnostics and immunotherapeutics, and IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage biopharmaceutical company pioneering a novel class of immunotherapies, have entered a preclinical research collaboration to explore the potential combinatory effect of their platform-based immunotherapies.

• Navidea Biopharmaceuticals Reports Third Quarter 2019 Financial Results

  11/7/2019

  Navidea Biopharmaceuticals, Inc., a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, announced its financial results for the third quarter ended September 30, 2019.

• Navidea Biopharmaceuticals to Host Third Quarter 2019 Earnings Conference Call and Corporate Update

  10/31/2019

  Navidea Biopharmaceuticals, Inc. announced it will host a conference call and webcast on Thursday, November 7, 2019 at 5:00 p.m. to discuss developments for the third quarter of 2019..

• Navidea Biopharmaceuticals Announces Positive Results of First Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis

  10/29/2019

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to announce positive results from the Company’s first interim analysis of its ongoing NAV3-31 Phase 2B study.

• Navidea Biopharmaceuticals to Present at the H.C. Wainwright 21st Annual Global Investment Conference

  9/6/2019

  Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that its Chief Executive Officer, Jed Latkin, will present a corporate overview of the Company at the H.C. Wainwright 21st Annual Global Investment Conference

• Navidea Biopharmaceuticals Announces Receipt of Notice of Award

  8/27/2019

  Navidea Biopharmaceuticals, Inc. announced receipt of the Notice of Award from the National Heart, Lung, and Blood Institute of the National Institutes of Health for its Small Business Technology Transfer Phase 1 grant application submitted in collaboration with the University of Alabama at Birmingham, titled “Gallium 68 Tilmanocept for PET Imaging of Atherosclerosis Plaques.” The grant award number is R41HL147640 and the award amount is $225,000.